Ex vivo γH2AX radiation sensitivity assay in prostate cancer: Inter-patient and intra-patient heterogeneity.

CONCLUSIONS: In prostate cancer inter-patient heterogeneity in tumour cell radiation sensitivity is pronounced and higher than intra-patient heterogeneity supporting the further development of the γH2AX ex vivo assay as a biomarker for individualized treatment.
PMID: 28919005 [PubMed - as supplied by publisher]

Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - September 14, 2017 Category: Radiology Authors: De-Colle C, Yaromina A, Hennenlotter J, Thames H, Mueller AC, Neumann T, Stenzl A, Scharpf M, Fend F, Ricardi U, Baumann M, Zips D, Menegakis A Tags: Radiother Oncol Source Type: research